228 related articles for article (PubMed ID: 28976766)
21. Nanoparticles targeting extra domain B of fibronectin-specific to the atherosclerotic lesion types III, IV, and V-enhance plaque detection and cargo delivery.
Yu M; Ortega CA; Si K; Molinaro R; Schoen FJ; Leitao RFC; Xu X; Mahmoudi M; Ahn S; Liu J; Saw PE; Lee IH; Brayner MMB; Lotfi A; Shi J; Libby P; Jon S; Farokhzad OC
Theranostics; 2018; 8(21):6008-6024. PubMed ID: 30613278
[TBL] [Abstract][Full Text] [Related]
22. The gastrin/cholecystokinin-B receptor on prostate cells--a novel target for bifunctional prostate cancer imaging.
Sturzu A; Klose U; Sheikh S; Echner H; Kalbacher H; Deeg M; Nägele T; Schwentner C; Ernemann U; Heckl S
Eur J Pharm Sci; 2014 Feb; 52():69-76. PubMed ID: 24211650
[TBL] [Abstract][Full Text] [Related]
23. EDB-FN targeted probes for the surgical navigation, radionuclide imaging, and therapy of thyroid cancer.
Li R; He H; Li X; Zheng X; Li Z; Zhang H; Ye J; Zhang W; Yu C; Feng G; Fan W
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2100-2113. PubMed ID: 36807768
[TBL] [Abstract][Full Text] [Related]
24. EDB Fibronectin-Specific SPECT Probe
Ye XX; Zhao YY; Wang Q; Xiao W; Zhao J; Peng YJ; Cao DH; Lin WJ; Si-Tu MY; Li MZ; Zhang X; Zhang WG; Xia YF; Yang X; Feng GK; Zeng MS
ACS Omega; 2017 Jun; 2(6):2459-2468. PubMed ID: 30023665
[TBL] [Abstract][Full Text] [Related]
25. In vivo MR/optical imaging for gastrin releasing peptide receptor of prostate cancer tumor using Gd-TTDA-NP-BN-Cy5.5.
Lin YH; Dayananda K; Chen CY; Liu GC; Luo TY; Hsu HS; Wang YM
Bioorg Med Chem; 2011 Feb; 19(3):1085-96. PubMed ID: 20493715
[TBL] [Abstract][Full Text] [Related]
26. Peptide targeted high-resolution molecular imaging of prostate cancer with MRI.
Wu X; Yu G; Lindner D; Brady-Kalnay SM; Zhang Q; Lu ZR
Am J Nucl Med Mol Imaging; 2014; 4(6):525-36. PubMed ID: 25250202
[TBL] [Abstract][Full Text] [Related]
27. MRI of breast tumor initiating cells using the extra domain-B of fibronectin targeting nanoparticles.
Sun Y; Kim HS; Park J; Li M; Tian L; Choi Y; Choi BI; Jon S; Moon WK
Theranostics; 2014; 4(8):845-57. PubMed ID: 24955145
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Targeted ECO/miR-200c Nanoparticles for Modulating Tumor Microenvironment and Treating Triple Negative Breast Cancer as Non-invasively Monitored by MR Molecular Imaging.
Schilb AL; Ayat NR; Vaidya AM; Hertz LM; Hall RC; Scheidt JH; Sun D; Sun Z; Gopalakrishnan R; Lu ZR
Pharm Res; 2021 Aug; 38(8):1405-1418. PubMed ID: 34389916
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and assessment of ZD2-(
Gao S; Qin J; Sergeeva O; Sergeev M; Qiao P; Roelle S; Avril N; Lee Z; Li Y; Lu Z
Am J Nucl Med Mol Imaging; 2019; 9(5):216-229. PubMed ID: 31772820
[TBL] [Abstract][Full Text] [Related]
30. Improved tumor-targeting MRI contrast agents: Gd(DOTA) conjugates of a cycloalkane-based RGD peptide.
Park JA; Lee YJ; Ko IO; Kim TJ; Chang Y; Lim SM; Kim KM; Kim JY
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):246-50. PubMed ID: 25449282
[TBL] [Abstract][Full Text] [Related]
31. MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent.
Zhou Z; Qutaish M; Han Z; Schur RM; Liu Y; Wilson DL; Lu ZR
Nat Commun; 2015 Aug; 6():7984. PubMed ID: 26264658
[TBL] [Abstract][Full Text] [Related]
32. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
33. Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging.
Park J; Kim S; Saw PE; Lee IH; Yu MK; Kim M; Lee K; Kim YC; Jeong YY; Jon S
J Control Release; 2012 Oct; 163(2):111-8. PubMed ID: 22964395
[TBL] [Abstract][Full Text] [Related]
34. Optimization of ZD2 Peptide Targeted Gd(HP-DO3A) for Detection and Risk-Stratification of Prostate Cancer with MRI.
Ayat NR; Qin JC; Cheng H; Roelle S; Gao S; Li Y; Lu ZR
ACS Med Chem Lett; 2018 Jul; 9(7):730-735. PubMed ID: 30034609
[TBL] [Abstract][Full Text] [Related]
35. Effective MR Molecular Imaging of Triple Negative Breast Cancer With an EDB-Fibronectin-Specific Contrast Agent at Reduced Doses.
Ayat NR; Vaidya A; Yeung GA; Buford MN; Hall RC; Qiao PL; Yu X; Lu ZR
Front Oncol; 2019; 9():1351. PubMed ID: 31850230
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of Gd-Based prostate cancer targeted magnetic resonance agents using prostate specific membrane antigen.
Yang JU; Kim S; Ahn JH; Kim MH; Kil HS; Chi DY; Lee KC; Lee YJ; Park JA
Biochem Biophys Res Commun; 2022 Jun; 607():152-157. PubMed ID: 35367828
[TBL] [Abstract][Full Text] [Related]
37. A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI.
Ye F; Wu X; Jeong EK; Jia Z; Yang T; Parker D; Lu ZR
Bioconjug Chem; 2008 Dec; 19(12):2300-3. PubMed ID: 19053180
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin.
Kim H; Lee Y; Lee IH; Kim S; Kim D; Saw PE; Lee J; Choi M; Kim YC; Jon S
J Control Release; 2014 Mar; 178():118-24. PubMed ID: 24462899
[TBL] [Abstract][Full Text] [Related]
39. cRGD peptide-conjugated icosahedral closo-B12(2-) core carrying multiple Gd3+-DOTA chelates for α(v)β3 integrin-targeted tumor imaging (MRI).
Goswami LN; Ma L; Cai Q; Sarma SJ; Jalisatgi SS; Hawthorne MF
Inorg Chem; 2013 Feb; 52(4):1701-9. PubMed ID: 23391150
[TBL] [Abstract][Full Text] [Related]
40. Modular Synthesis of DOTA-Metal-Based PSMA-Targeted Imaging Agents for MRI and PET of Prostate Cancer.
Schmitthenner HF; Dobson DE; Jones KG; Akporji N; Soika DQM; Nastiuk KL; Hornak JP
Chemistry; 2019 Nov; 25(61):13848-13854. PubMed ID: 31364213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
